bet for dollars->a dream?, page-23

=== Pipleline, which DNDN now is dreaming, how about PRR ===
1. Two years ago, when the FDA overruled the Biologics Advisory Committee and declined to approve Provenge, the company stopped early stage trials of the exact same technology platform in breast cancer and head & neck cancer.

2. With the cash coming in from the forthcoming marketing partnership, those trials can be restarted. On the recent conference call, DNDN management said:

2.1> As you know, Provenge employs our novel proprietary Antigen Delivery Cassette technology that may be leveraged to develop similar products to treat breast, colon, bladder, kidney, and multiple other types of cancer.

2.2> The IMPACT results renew and validate our confidence in this platform technology and our ability to extend its benefits across other cancer types.

2.3> We will be evaluating a more comprehensive development plan to expand our cancer immunotherapy product pipeline.

***
1. It is most difficult for anyone and any company to get his/its first bucket of gold in cash.
2. PRR is very confident about its CVav technology.
3. It would/should evaluate the crucial path of DNDN phase III trial and be sure to get the statical reliability of safety and efficacy within FDA's requirement.
4. Now I get the idea why PRR keeps to say DNDN shows the pathway to pass the Phase III trial for its commercialization.